AgeneBio to Present at BIO Investor Forum 2015

Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.

« back to Press Releases

October 6, 2015

AgeneBio to Present at BIO Investor Forum 2015

BALTIMORE, MD, October 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the BIO Investor Forum. The conference will be held October 20 to 21 at the Parc 55 San Francisco. CEO Jerry McLaughlin will present on Wednesday, October 21, at 9 am Pacific time.

About AgeneBio
AgeneBio, Inc., is a development-stage CNS biopharmaceutical company developing innovative therapeutics aimed at preserving and restoring brain function for unserved patients afflicted with neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease. If approved, AgeneBio’s Phase 3-ready lead candidate AGB101 will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to and delay the onset of Alzheimer’s dementia. AgeneBio expects to initiate the HOPE4MCI Phase 3 clinical trial of AGB101 in early 2016. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at and follow us on Twitter @AgeneBio.

Media Contacts
Jennifer Guinan | Sage Strategic Marketing | 610.410.8111
Hilary Lefebvre | Acadia Co. | 212.300.4929